Greer Laboratories, Stallergenes, Ares Life Sciences deal

Ares Life Sciences will combine its majority-owned Stallergenes company and wholly owned Greer Laboratories subsidiary to form new subsidiary Ares Allergy Holding plc, which Ares plans on listing on Euronext Paris. Stallergenes’ shareholders will receive one share of Ares Allergy stock per share, which the companies said values Stallergenes’ stock at one-and-a-half times Greer’s. Stallergenes closed at EUR58.50 on March 2, the day before the deal was announced. The company had 13,864,433 shares out on Dec. 31, 2014. Ares Life Sciences would have 86% ownership of the new subsidiary. Stallergenes said it expects the deal to close next quarter. ...